Global Allogenic CAR-T Cell Therapy Market Report and Forecast 2024-2032

Allogenic CAR-T Cell Therapy Market Size

The global allogenic CAR-T cell therapy market size was valued at USD 0.87 billion in 2023, driven by the rising advancements in gene technology across the globe. The market is expected to grow at a CAGR of 15.6% during the forecast period of 2024-2032, with the values likely to attain USD 3.24 billion by 2032.

Allogenic CAR-T Cell Therapy Market Outlook

• The innovation in gene editing methods like CRISPR/Cas9 is improving the safety and effectiveness of allogeneic CAR-T cell therapy by eliminating GvHD effects and improving treatment outcomes. Such enhancements are expected to boost market growth in the coming years.

• In April 2024, Caribou Biosciences received FDA clearance for allogeneic CAR-T CB-010 designed for lupus nephritis and non-renal lupus treatment. This has emphasized the application of allogenic CAR-T cells beyond oncology, which may further boost the market demand.

• North America constitutes a significant market share of allogeneic CAR-T cells, driven by a well-developed healthcare system, higher investment in novel therapies, and favourable policies.

Allogenic CAR-T Cell Therapy Market Overview

Allogeneic CAR-T cell technology involves genetically engineered T-cells from unrelated healthy donors to recognize antigens on cancer cells. These modified cells use the body's immune system to identify and target cancer cells. This approach is intended to improve the safety and effectiveness of the treatment by looking for the difficulties related to personalized autologous treatments. It also aims to increase the possibility of application and effectiveness in targeting various kinds of cancer.

Allogenic CAR-T Cell Therapy Market Growth Drivers

Rising Prevalence of Cancer Significantly Drives the Market Growth

The American Cancer Society revealed that the United States alone recorded around 1,958,310 new cancer cases while 609,820 cancer-related deaths were observed in 2023. The increasing incidence and prevalence of cancer along with the growing number of patients who display failure in response to multiple therapies fuel the allogenic T-cell therapy market growth across the world.

Furthermore, more cases of cancer are being diagnosed in both geriatric and pediatric patients, bolstering the demand for effective and healthier treatment to enhance the quality of life of the patient.

Increasing Investment and Research Initiatives to Boost Rising Allogenic CAR-T Cell Therapy Market Demand

Allogeneic CAR-T cell therapy is gaining attention with rising investment and research activities in various cancer types. This investment is being spurred by improved methods of genetic engineering, fine-tuning production procedures, and widened usage of enzymatic products in the treatment of solid cancers apart from blood cancers. The rising emphasis on investments and research is a key driver of market growth as it fosters innovation, therapeutic outcomes, and the international expansion of allogeneic CAR-T cell therapies.

Allogenic CAR-T Cell Therapy Market Trends

Recent Developments in the Allogenic CAR-T Cell Therapy Market

In April 2024, CARibou Biosciences received FDA approval for its CD19-specific allogeneic CAR-T CB-010 for lupus nephritis and extrarenal lupus treatment. The latest approval is based on the ANTLER trial for third-line treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The first clinical trial of GALLOP Phase 1 is expected to start by the end of 2024, as it aims to assess the effectiveness of CB-010 in targeting CD19-positive B cells that are responsible for autoantibody synthesis and autoimmune response reinforcement. The therapy prospect is to develop a new treatment plan for lupus with a focus on the problems, such as organ damage. This trial will also address the matching between donors and patients in a partial HLA to boost clinical results.

In July 2023, Poseida Therapeutics received FDA approval on the investigational new drug for P-CD19CD20-ALLO1, which is an allogeneic dual CAR-T cell product for the treatment of relapsed or refractory B-cell malignancies. It employs Poseida’s non-viral piggyBac® DNA Delivery System to add two functional CARs and intends to address the antigen escape in CD19-only products. Phase 1 will involve 70 patients and is primarily designed to evaluate the safety, tolerability, and, to some extent, efficacy.

Allogenic CAR-T Cell Therapy Market Segmentation

Market Breakup by Therapeutic Area

• Oncological Disorders

• Neurological Disorders

• Musculoskeletal Disorder

• Autoimmune / Inflammatory Disorders

• Post-Transplant Infections

• Others

Market Breakup by Indication

• Bone Disorder

• Critical Limb Ischemia

• Crohn’s Disease

• Diabetic Foot Ulcer

• Graft versus Host Disease

• Leukemia

• Lymphoma

• Myelodysplastic Syndrome

• Cytomegalovirus Infection

• Others

Market Breakup by Source of Cell

• Peripheral Blood

• Bone Marrow

• Umbilical Cord Blood

• Adipose Tissue

Market Breakup by Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

Global Allogenic CAR-T Cell Therapy Market Share

Market Segmentation by Therapeutic Area is Projected to Experience Significant Growth

Based on the therapeutic areas, the market is divided into oncological disorders, neurological disorders, musculoskeletal disorder, autoimmune / inflammatory disorders, post-transplant infections and others. Oncological disorders are expected to hold a significant market share in the forecast period. This can be attributed to the rising incidence of cancer and cancer-associated mortality rates across the globe.

Allogenic CAR-T Cell Therapy Market Analysis by Region

Based on the region, the market is divided into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Among these, North America dominates the market owing to the availability of early and established healthcare systems, increased adoption of innovative therapies, and favorable regulatory environments that support clinical trials and product launches.

Europe also holds a substantial share as it is equipped with a well-developed infrastructure to conduct research and development activities. Cooperation between universities and industries, and reasonable reimbursement policies also aid market enhancement. The Asia Pacific is expected to become another prominent market for allogeneic CAR-T cells due to factors such as growing concern about the healthcare budget, the increasing incidence of cancer, and the growing availability of innovative treatment options.

Leading Players in the Global Allogenic CAR-T Cell Therapy Market

The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:

Artiva Biotherapeutics Inc

The company Artiva Biotherapeutics was established in 2019 and is in San Diego. It is engaged in the development of allogeneic natural killer (NK) cell therapies. Their pipeline consists of the NK cell therapy AB-101, which is in different phases of the clinical trial for different types of cancer, and the AB-201 program for different solid tumors, which is still in the preclinical stage. These therapies are used to boost anti-tumor activity and may be added to MAbs and other treatments.

 Allogene Therapeutics Inc.

Allogene Therapeutics was founded in 2017 and is in San Francisco, California. This biotechnology company focuses on allogeneic CAR-T cell therapies. The company’s pipeline comprises ALLO-501/ALLO-501A for the treatment of non-Hodgkin lymphoma, ALLO-715 for multiple myeloma cancer, the CD70-directed ALLO-316 for renal cell carcinoma and other solid cancers, along with ALLO-605, a TurboCAR™ therapy that targets BCMA. These commercial therapies are intended to replace the need for manufacturing treatments tailored to a particular patient’s tumor type.

Atara Biotherapeutics Inc.

Atara Biotherapeutics was established in 2012 and is proposing allogeneic CAR-T and T-cell immunotherapies. ATA3271 is working for solid tumors with Bayer for targeting mesothelin, and ATA3219 for CD19-positive B-cell malignancies. Atara employs EBV T-cell lines to develop drugs for cancer, autoimmune, or viral disease treatments.

Cellenkos, Inc.

Founded in 2016 and based in Houston, USA, Cellenkos engages in the generation of allogeneic, cord blood-derived T regulatory (Treg) cell therapies. CK0801 for inflammatory and autoimmune diseases and CK0802 for GvHD and inflammatory diseases are their main products. Cellenkos uses the immunosuppressive property of Treg cells to control immune reactions.

Other companies include Cell2Cure Apps, Celularity, Inc., Cellular Biomedicine Group, Chabiotech Co., Ltd., and CRISPR Therapeutics AG.

Kindly note that this only represents a partial list of companies, and the complete list has been in the report.

Key Highlights of the Report

Key Questions Answered in the Allogenic CAR-T Cell Therapy Market

• What was the global allogenic CAR-T cell therapy market value in 2023?
• What is the global allogenic CAR-T cell therapy market forecast outlook for 2024-2032?
• What are the regional markets covered in the EMR report?
• What are the major factors aiding the global allogenic CAR-T cell therapy market demand? 
• What are the market's major drivers, opportunities, and restraints? 
• What is the market segmentation based on the therapeutic area?
• What is the market breakup based on indication?
• What is the market segmentation based on the source of cell?
• Which regional market is expected to lead the market share in the forecast period? 
• Which country is expected to experience expedited growth during the forecast period? 
• What are the major global allogenic CAR-T cell therapy market trends?
• How does the rise in the geriatric population impact the market size?
• Who are the key players involved in the allogenic CAR-T cell therapy market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?